ASLAN Pharmaceuticals Limited was incorporated in the Cayman Islands in June 2014. The company is a biopharmaceutical company focused on clinical-stage immunology, developing innovative therapies to transform patients' lives. The company's product portfolio is led by eblasakimab (also known as ASLAN 004), a potential first-in-class human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking the signaling of the two pro-inflammatory cytokines IL-4 and IL-13, which are at the core of triggering atopic dermatitis symptoms such as skin redness and itching. 

ASLN(Delisted)

ASLN Profile